Professional
Added to YB: 2024-06-27
Pitch date: 2024-06-21
BDX [bullish]
Becton, Dickinson and Company
-13.27%
current return
Author Info
No bio for this author
Company Info
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Market Cap
$56.6B
Pitch Price
$231.62
Price Target
300.00 (+49%)
Dividend
2.12%
EV/EBITDA
11.84
P/E
34.09
EV/Sales
3.48
Sector
Health Care Equipment and Supplies
Category
growth
Becton, Dickinson and Company: Raising EPS estimates
BDX: Buy, $300 PT. New products & M&A driving growth. Alaris pump relaunch regaining market share. Critical Care acquisition accretive. Raised FY24 EPS est. to $13.02, FY25 to $14.45. Strong Q2: EPS +10.8%, rev +5.7% organic. Margins improving. 5.5-6.25% organic growth expected. 1.63% dividend yield. Risks: integration, regulation, FX. Trades 16.2x FY25 EPS, below 21.3x peer avg.
Read full article (3 min)